CD24Fc for GVHD prevention in MPN allo-HSCT

Current understanding

CD24Fc (OncImmune) is an investigational fusion protein being developed as a non-JAK-inhibitor approach to prevent graft-versus-host disease in MPN patients undergoing allogeneic transplant. It expands the GVHD prophylaxis landscape beyond the JAK inhibitor class (ruxolitinib, itacitinib, gecacitinib, momelotinib) by targeting innate inflammatory pathways via CD24-Siglec interactions. Currently at the FDA-funded preclinical/early-trial stage with no clinical efficacy data yet reported.

Evidence log

• Foundation — FDA Awards $18 Million in Grants for Advancing Treatment of Rare Diseases: cross-connection with peritransplant-ruxolitinib-gvhd: Both target GVHD prevention in MPN allo-HSCT but via distinct mechanisms — CD24Fc modulates innate inflammation while peri-transplant ruxolitinib/JAK inhibitors target JAK-STAT signaling, raising the question of combinability. (novelty: 3)

Open questions

Related